The PennZone

  • Home
  • Non-profit
  • Music
  • Books
  • Entertainment
  • Marketing
  • Legal
  • Health
  • Automotive

Enterin Announces Appointment of New CEO
The PennZone/10088808

Trending...
  • Harvard Educated Board Certified Endodontist Joins Pearlfection Dentistry
  • Wilson Venture Capital to Launch News Organization; Will Name Trevor Wilson CEO
  • Turnstone Creative Welcomes Giovanni Amodei as Manager of Strategic Growth
PHILADELPHIA, Oct. 16, 2020 /PRNewswire/ -- Enterin, Inc., a privately held, CNS-focused pharmaceutical company based in Philadelphia and developing novel compounds to treat neurodegenerative diseases, announces the appointment of David McCullough as Chief Executive Officer.

With over 30 years of pharma/biotech experience, Mr. McCullough is a demonstrated strategic, creative, and accomplished leader. With executive and board director experience in startup and established companies, David brings expertise in both the private and public sector. He has a deep understanding of drug development, clinical and regulatory strategy, commercial, finance, IP, manufacturing and operations. Mr. McCullough has a proven track record of building highly skilled, energetic, cross-functional teams both domestically and globally. He has strong experience moving products from early development to launch, including orphan drugs and billion-dollar brands. At Merck, he played a lead role in the $13.5B acquisition of Serono Biotech, and he was honored by the Merck family as a top contributor in corporate development. Additionally, Mr. McCullough has held leadership positions in Allergopharma/EMD Serono and BioCryst. He is interested in Enterin as he has a personal passion for the neurodegenerative therapeutic area and the patient population that can be served with better therapeutic outcomes. "I am thrilled to have the opportunity to join this team that is pioneering the science behind truly innovative approaches in the treatment of neurodegenerative diseases," says McCullough.

More on The PennZone
  • netElastic Announces vBNG And CGNAT 2.0 General Availability
  • Postmortem Pathology Highlights Private Autopsy Options for Las Vegas Families During Summer Months
  • Postmortem Pathology Offers Sacramento Families Independent Answers on a Short Timeline
  • Philly ECM Programming Announces Mobile Module Programming for Philadelphia Repair Shops
  • NEW Three Fully Furnished Single-Family Model Homes at Heritage at South Brunswick

Enterin's founders and chairmen, Michael Zasloff, MD, PhD and Denise Barbut MD, FRCP reciprocated the sentiment. They said, "We are delighted that David has agreed to join Enterin. His extensive experience in the pharmaceutical industry will supplement the scientific and medical expertise of the existing management team."

About Enterin Inc.

Enterin Inc. is the first company to develop novel compounds that repair the dysfunctional gut-brain axis in patients with neurodegenerative diseases. Enterin Inc. is pioneering the medical community's understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut and the early onset and chronic progression of neurodegenerative disease. The lead compound, ENT-01, displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson's disease. Enterin Inc. is now progressing ENT-01 through clinical trials in an attempt to reverse the neurologic symptoms of Parkinson's disease.

More on The PennZone
  • After 35 Years, Christian Radio Host Marina Maria Publishes the Novel She Never Forgot
  • Freight Broker 911 CEO and President Milton Collier Is Rebuilding the Path Into Freight Brokerage
  • Boston Industrial Solutions Launches New and Improved Siliart Website for Silicone Decorators
  • TrueNorth to Participate in 2026 Adams County Giving Spree
  • Roots for Boots Announces Rations for the Ranks to Replace MilitaryShare Beginning November 10

For more information, please visit www.enterininc.com.

Contact
Enterin Inc.
[email protected]

Related Images

enterin-logo.jpg
Enterin Logo

SOURCE Enterin Inc.
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • BJJ App mmaGPT Expands Academy Program to Support Jiu-Jitsu Instructors with AI Technique Coaching
  • Ten Ten Ten Announces Maximizing Clinical Operations
  • Turnstone Creative Welcomes Giovanni Amodei as Manager of Strategic Growth
  • CardsNearby Launches Free Nationwide Directory of Card Shows and Local Card Shops for Collectors
  • American Garden Rose Selections™ Announces 2027 Winners
  • Crossroads4Hope Launches Blood Cancer Resource Hub
  • Wilson Venture Capital to Launch News Organization; Will Name Trevor Wilson CEO
  • NIL Club Data Shows Brands Are Looking Beyond Follower Counts in College Sports
  • Georgia's Magical Nights of Lights Bigger and Brighter for 2026
  • Bicentennial Occult Outing Alternative History Video Series Launches for Spooky Season
  • Harvard Educated Board Certified Endodontist Joins Pearlfection Dentistry
  • NYC Banners Delivers High-Stakes UN General Assembly Backdrop for the US Department of State Event
  • OneVizion Appoints Energy Infrastructure Executive Walt Farrell to Board of Directors
  • Tampa Bay Reporter Launches with a Mission to Deliver Local News with National Reach
  • "JACKIE the STRIPPER," Starring Charlotte Kirk and The PUSSYCAT DOLLS' Kimberly Wyatt, Now Streaming on PRIME
  • Migguel Anggelo Celebrates the Immigrant Experience, Latino Identity, and the Power of Iconic Latin Rhythms During Hispanic Heritage Month
  • Indianapolis Criminal Defense Firm Rigney Law LLC Relaunches Criminal Law Podcast "Tales from the Brown Desk"
  • 3ptechies Makes Its Articles Audio-Ready With Instaread Voice Technology
  • Genuine Hospitality, LLC Selected to Operate Fairfield Inn & Suites Tampa Wesley Chapel
  • Pregis to Highlight EPR Expertise, Sustainable Packaging Solutions and Live Automation Demonstrations at Pack Expo International 2026

Popular on PennZone

  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Mandeville Pests May Pose Serious Health Risks for Your Family
  • Garage door installation or repair in Minnesota? Which makes more sense for your family?
  • The Culture and Travel Report Enters a New Chapter as Travel and Hospitality Brands Take Notice
  • STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
  • New Bethany's 35th Annual Souper Day to Spotlight Connection Between Health, Hunger and Housing
  • Regcrest LLC Publishes Free 50-State Tax Account Closure Checklist Tool
  • A New Tale Band Makes 9/11 Tribute Song "The Twins" Free for Ceremonies and School Programs
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
  • Dion Abadi Publishes Free Collector Tips Hub for Art and Jewelry Buyers

Similar on PennZone

  • RAS AP Consulting Issues National Compliance Alert and Launches Q4 2026 AP Readiness Program Ahead of IRS FIRE → IRIS Cutover
  • Claude Zdanow named Managing Director in Miami, Florida
  • Pregis Launches Sharp InfinX: On-Demand Rightsized Mailing System Delivering a Precision-Sized Mailer for Every Order
  • Freight Broker 911 CEO and President Milton Collier Is Rebuilding the Path Into Freight Brokerage
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Phoenix
  • Sky Quarry's Big Turning Point: CEO Marcus Laun Outlines the Next Phase for N A S D A Q: SKYQ
  • Guardian Data Opens 42,000-Square-Foot Moonachie Facility, Doubling New Jersey Capacity
  • SecureMaine 2026 is Here -- Thursday October 8th!
  • ResC4EU Final Event at KOMPOZYT-EXPO 2026 – Building Resilient European Supply Chains
  • NIL Club Data Shows Brands Are Looking Beyond Follower Counts in College Sports
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us